Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
Financial Services
$10.38 +0.91%
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
52W Low $11.00High $16.75
Volume 1.05M
Average 0.55M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$200.62M
FY 2025 · Annual
Investing Cash Flow
$116.77M
FY 2025 · Annual
Financing Cash Flow
$28.06M
FY 2025 · Annual
-69.3% YoYCash Flow Statement
USD
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (181.38M) | (222.97M) |
| Depreciation & Amortization | 15.35M | 13.18M |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 19.47M | 20.58M |
| Change in Working Capital | 28.12M | (14.62M) |
| Accounts Receivables | (213K) | 308K |
| Inventory | 0 | 0 |
| Accounts Payables | 3.5M | (2.13M) |
| Other Working Capital | 24.83M | (12.79M) |
| Other Non-Cash Items | 702K | 3.21M |
| Operating Cash Flow | (117.75M) | (200.62M) |
| Capital Expenditures | (3.45M) | (3.51M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (282.98M) | (164.73M) |
| Sales of Investments | 228.69M | 285.01M |
| Other Investing Activities | 10K | 0 |
| Investing Cash Flow | (57.73M) | 116.77M |
| Debt Repayment | (11.12M) | (8.16M) |
| Common Stock Issued | 0 | 0 |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 6.13M | 14.25M |
| Financing Cash Flow | 91.33M | 28.06M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | (84.15M) | (55.79M) |
| Free Cash Flow | (121.2M) | (204.13M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$223.0M
+ D&A$13.2M
+ Stock-Based Comp$20.6M
+ Deferred Tax$0
- Working Capital-$14.6M
+ Other Non-Cash$3.2M
= Operating Cash Flow-$200.6M
- Capex-$3.5M
= Free Cash Flow-$204.1M
Analysis
FY2025 free cash flow is -$204.1M. FCF conversion is 91.6% of net income. Operating cash flow was -$200.6M, with capex of -$3.5M. The largest bridge item is Stock-Based Comp at $20.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 3, 2026 |
Does GENB generate free cash flow?
Generate Biomedicines, Inc. (GENB) generated -$204.13M of free cash flow in fiscal 2025.
How much operating cash flow does GENB produce?
Operating cash flow was -$200.62M, before capital expenditures of $3.51M.
Continue the stock analysis
Jump to another research area for this company.